People With Blood Type O Might Be At A Reduced Risk Of Severe COVID19 Disease And Its Implications

Two new studies have revealed that there is a link between people with O blood type and lower chances of being diagnosed with severe COVID19 infection. These studies have shown that people with O blood group, who have been diagnosed with COVID19, will have milder symptoms than others. Experts have not been able to find out the cause and effect of the statistical link in the study. One study has been published in Denmark and another study with the same findings has been released in Canada. However, experts have said that there is a need for further studies for more substantial conclusions. Experts have said that the O blood group plays a significant role in people’s susceptibility to COVID19 infection.

The study published in Denmark has revealed that only 38.4 percent of people with O blood type have tested positive for COVID19 out of 7422 Danish people. The study has reported that people with blood type O make up only 41.4 percent of nearly 2.2 million of the untested population. People with blood type A contribute to 44.4 percent of people who have been diagnosed with the disease. They make up 42.2 percent of people who have not been tested yet. The Canadian study has analyzed 95 patients who have been diagnosed with COVID19. The study shows that people with A and AB have required a ventilator as compared to 61 percent of people with blood type O and B. People with blood type O and B have stayed only for 9 days in the intensive care as compared to those with A and AB blood groups, who have spent nearly 13.5 days in the intensive care.

Dr. Mypinder Sekhon, the author of the Canadian study has said that authorities need to conduct more study to consider this as a definitive marker. It is uncertain whether this link is a certain kind of protection for O blood type people or some kind of vulnerability linked to other blood groups. Experts have said that the findings of the study should not change the way people have been taking their daily lives so far. Both studies have been published in the Journal of Blood Advances.